Patents Assigned to Antares Pharma IPL AG
-
Patent number: 9682087Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.Type: GrantFiled: December 17, 2010Date of Patent: June 20, 2017Assignees: The Population Council, Inc., Antares Pharma IPL AGInventors: Regine Sitruk-Ware, Dario Norberto Ramon Carrara, Arnaud Grenier
-
Patent number: 8980290Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.Type: GrantFiled: November 6, 2009Date of Patent: March 17, 2015Assignee: Antares Pharma IPL AGInventors: Dario Norberto R. Carrara, Arnaud Grenier
-
Patent number: 8980309Abstract: This invention relates to novel transdermal or transmucosal pharmaceutical formulation having an active agent of testosterone which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The solvent system of the formulation includes a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of the active agent in a pharmaceutical formulation.Type: GrantFiled: May 12, 2011Date of Patent: March 17, 2015Assignee: Antares Pharma IPL AGInventors: Dario Norberto R. Carrara, Arnaud Grenier
-
Patent number: 8652491Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.Type: GrantFiled: August 3, 2012Date of Patent: February 18, 2014Assignee: Antares Pharma IPL AGInventors: Dario Norberto R. Carrara, Arnaud Grenier
-
Patent number: 8647665Abstract: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: August 13, 2012Date of Patent: February 11, 2014Assignee: Antares Pharma IPL AGInventors: Stephen M. Simes, Leah M. Lehman
-
Publication number: 20140037713Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially live of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for hyperhidrosis with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.Type: ApplicationFiled: March 8, 2013Publication date: February 6, 2014Applicant: ANTARES PHARMA IPL, AGInventors: Paul Wotton, Holger Kraus, Peter L. Sadowski
-
Publication number: 20130045953Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.Type: ApplicationFiled: December 17, 2010Publication date: February 21, 2013Applicants: ANTARES PHARMA IPL AG, THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Dario Norberto Ramon Carrara, Arnaud Grenier
-
Patent number: 8338400Abstract: Methods, formulations, and devices for providing transdermal or transmucosal delivery of testosterone to female subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.Type: GrantFiled: September 7, 2011Date of Patent: December 25, 2012Assignee: Antares Pharma IPL AGInventors: Leah M. Lehman, Stephen M. Simes
-
Publication number: 20120308648Abstract: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: ApplicationFiled: August 13, 2012Publication date: December 6, 2012Applicant: ANTARES PHARMA IPL AGInventors: Stephen M. Simes, Leah M. Lehman
-
Publication number: 20120294934Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Applicant: Antares Pharma IPL AGInventors: Dario Norberto R. CARRARA, Arnaud GRENIER
-
Patent number: 8268346Abstract: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: April 19, 2007Date of Patent: September 18, 2012Assignee: Antares Pharma IPL AGInventors: Stephen M. Simes, Leah M. Lehman
-
Patent number: 8067399Abstract: Methods, formulations, and devices for providing transdermal or transmucosal delivery of active agents to subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.Type: GrantFiled: May 24, 2006Date of Patent: November 29, 2011Assignee: Antares Pharma IPL AGInventors: Leah M. Lehman, Stephen M. Simes
-
Patent number: 7470433Abstract: The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: March 30, 2007Date of Patent: December 30, 2008Assignee: Antares Pharma IPL AGInventors: Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse, Stephen M. Simes, Leah M. Lehman
-
Patent number: 7425340Abstract: A transdermal or topical composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects.Type: GrantFiled: May 2, 2005Date of Patent: September 16, 2008Assignee: Antares Pharma IPL AGInventors: Arnaud Grenier, Dario Norberto R. Carrara, Celine Besse
-
Patent number: 7404965Abstract: A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of alprazolam to a subject, which includes as a permeation enhancing mixture a fatty component in an amount of 0.1% to 20% by weight which is one of (a) a saturated fatty alcohol of formula CH3—(CH2)n—CH2OH, a saturated fatty acid of formula CH3—(CH2)n—CH2COOH, (b) an unsaturated fatty alcohol of formula CH3(CnH2(n?1))—OH, or (c) a fatty acid of formula CH3(CnH2(n?1))—COOH, wherein n is an integer of between 8 and 22; and a vehicle that includes a C1-C4 alkanol, a polyalcohol, and water.Type: GrantFiled: December 4, 2006Date of Patent: July 29, 2008Assignee: Antares Pharma IPL AGInventors: Dario Carrara, Gabriel Porto, Jorge Rodriguez
-
Patent number: 7387788Abstract: The present invention comprises non occlusive compositions for transdermal delivery of nicotine, and more particularly pharmaceutically acceptable salts thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically comprise a mixture of water and alcohol, and a solvent system having a mono alkyl ether of diethylene glycol and a glycol present in specified ratios and in specific amounts, wherein the pH of the gel is usually between a pH of 5.5 and 7. The compositions may include further components, for example, the hydroalcoholic vehicle may further comprise additional penetration enhancer(s), buffering agent(s), antioxidant(s), stabilizer(s) and/or gelling agent(s). The invention also relates to a method for the sustained delivery of nicotine pharmaceutically acceptable salts to treat a variety of conditions and disorders.Type: GrantFiled: July 24, 2006Date of Patent: June 17, 2008Assignee: Antares Pharma IPL AGInventors: R. Dario Norberto Carrara, Arnaud Grenier, Celine Besse
-
Patent number: 7335379Abstract: This invention relates to novel transdermal or transmucosal pharmaceutical formulation which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The novel formulation includes at least one pharmacologically active ingredient, and a solvent system having a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of an active agent in a pharmaceutical formulation.Type: GrantFiled: March 7, 2006Date of Patent: February 26, 2008Assignee: Antares Pharma IPL AGInventors: R. Dario Norberto Carrara, Arnaud Grenier, Celine Besse
-
Patent number: 7214381Abstract: The present invention refers to a pharmaceutical composition suitable for the transdermal or transmucosal administration of one or more active agents, in form of a gel or a solution, comprising as a permeation enhancers a combination of: a) saturated fatty alcohol of formula CH3—(CH2)n—CH2OH or saturated fatty acid CH3—(CH2)n—CH2COOH wherein n is an integer number 8÷22, preferably 8÷12, most preferably 10, or unsaturated fatty alcohol or fatty acid of formula: CH3(CnH2(n-1))—OH or CH3(CnH2(n-1))—COOH wherein n is an integer number 8÷22, b) a ternary vehicle or carrier consisting of a C1÷C4 alkanol, a polyalcohol in particular propylenglycol and water, c) optionally also a monoalkylether of diethylenglycol.Type: GrantFiled: August 3, 2001Date of Patent: May 8, 2007Assignee: Antares Pharma IPL AGInventors: Dario Carrara, Gabriel Porto, Jorge Rodriguez
-
Patent number: 7198801Abstract: The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: March 10, 2004Date of Patent: April 3, 2007Assignee: Antares Pharma IPL AGInventors: Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse, Stephen M. Simes, Leah M. Lehman
-
Patent number: 6696085Abstract: The present invention provides for the use of a polymer of the acrylic type as a disintegration agent.Type: GrantFiled: July 15, 1999Date of Patent: February 24, 2004Assignee: Antares Pharma IPL AGInventors: Isabelle Rault, Etienne Pionnier